Citadel Advisors
NUVB icon

Citadel Advisors’s Nuvation Bio NUVB Stock Holding History

Citadel Advisors’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$712K Sell
166,000
-179,100
-52% -$998K ﹤0.01% 8456
2025
Q4 		$3.09M Buy
345,100
+17,400
+5% +$108K ﹤0.01% 5099
2025
Q3 		$1.21M Buy
327,700
+220,900
+207% +$602K ﹤0.01% 7122
2025
Q2 		$208K Sell
106,800
-46,700
-30% -$97.3K ﹤0.01% 10591
2025
Q1 		$270K Sell
153,500
-69,600
-31% -$158K ﹤0.01% 9821
2024
Q4 		$593K Buy
223,100
+124,400
+126% +$320K ﹤0.01% 8182
2024
Q3 		$226K Buy
98,700
+92,200
+1,418% +$281K ﹤0.01% 9898
2024
Q2 		$19K Buy
6,500
+3,600
+124% +$11K ﹤0.01% 12694
2024
Q1 		$10.6K Buy
2,900
+2,500
+625% +$4.8K ﹤0.01% 13453
2023
Q4 		$604 Buy
400
+200
+100% +$257 ﹤0.01% 13990
2023
Q3 		$268 Buy
+200
New +$333 ﹤0.01% 14102
2021
Q3 		– Sell
-38,500
Closed -$358K – 14393
2021
Q2 		$358K Buy
+38,500
New +$439K ﹤0.01% 10839

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors's NUVB Position: Q1 2026 in Review

Citadel Advisors increased its Nuvation Bio (NUVB) stake by 1,430% in Q1 2026, buying an estimated $10.8M and bringing the position to 2,065,411 shares worth $8.86M. The position accounts for ﹤0.01% of the portfolio, ranked #3425.

Citadel Advisors first reported a position in NUVB in Q4 2020 and has held it in 22 quarters since. The position peaked at $68.8M in Q1 2021. 231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

  • Citadel Advisors held 2,065,411 shares of Nuvation Bio worth $8.86M as of Q1 2026.
  • Citadel Advisors bought 1,930,412 Nuvation Bio shares in Q1 2026, an estimated $10.8M.
  • Nuvation Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3425 holding.
  • Citadel Advisors first reported a position in Nuvation Bio in Q4 2020 and has held it in 22 quarters since.
  • Citadel Advisors's Nuvation Bio position peaked at $68.8M in Q1 2021.
  • 231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.